listing in 2015, page-7

I sense the company has struggled with it's regulatory interpretation, marketing strategy and product revenue forecasting from the outset. I can't even begin to outline some of the statements we saw during the initial approval of Ropren and the proposed marketing and development strategies for Ropren and Bio A including the potential revenue forecasts.

Corporate decision making and regulatory hurdles aside, I believe the product is brilliant but their path to solid revenue is unlikely to be driven by Bio A and the retail market. Pharmaceuticals are where it's at.... and unless Ropren jumps from the stables as a treatment for Liver Disease, it's going to be a very, very long road to meaningful shareholder growth.

Ropren, raw material sales, Bio A, cosmetics, Bio I, Sauna Therapy Products, Gel's.... probably in order of potential for their current product stream. Though at the moment I think Bio A is leading.

On another note, this is one very long suspension that's for sure.